MultiplAI Health develops a universal precision screening technology that combines RNA sequencing and artificial intelligence to produce a simple whole-blood liquid biopsy for cardiovascular and other complex diseases. The test is intended to deliver highly accurate risk assessments at a fraction of the cost of current screening options and to enable early detection and progressive tracking of CVD risk. The company says the universal test will help healthcare professionals identify cardiovascular risks before symptoms appear. MultiplAI launched in the UK in 2020 with support from Illumina Accelerator Cambridge and has since initiated clinical studies in the UK and Argentina. The firm maintains clinical and lab operations in Cambridge and Buenos Aires and is opening operations and partnerships in the United States. The $2.7M seed financing will be used for technical validation of its proprietary RNA-based, AI-driven product, team building, and US expansion.

Total raised

$3M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023